Speakers - Sachs Associates
Speakers - Sachs Associates
Speakers - Sachs Associates
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
CONTACT<br />
Oliver Middendorp<br />
CBO & Co-CEO<br />
ADDRESS<br />
Numab AG<br />
Einsiedlerstrasse 34<br />
CH-8820 Wädenswil<br />
Switzerland<br />
TELEPHONE<br />
+41 44 533 0471<br />
FAX<br />
+41 44 533 0470<br />
EMAIL<br />
o.middendorp@numab.com<br />
YEAR FOUNDED<br />
2011<br />
Numab<br />
www.numab.com<br />
FINANCIAL SUMMARY<br />
Up to CHF 5 million seed money provided through industry collaboration.<br />
COMPANY PROFILE<br />
Numab is a Swiss biotech company focusing on the discovery and development of therapeutic antibodies.<br />
Numab is a young company lead by a Management with proven track record in the biotech industry (4 out of 5<br />
Management members have been long lasting employees in key positions at ESBATech).<br />
Numab applies a high-throughput selection system that increases the antibody discovery success rates<br />
by magnitudes and allows to efficiently identify best-in-class and/or first in class antibodies. The discovery<br />
engine is particularly well suited to detect antibodies against unconventional targets such as multi-spanning<br />
transmembrane proteins (e.g. GPCRs or ion channels).<br />
Numab is pursuing proprietary antibody programs in autoimmune diseases and pain, however, also applies its<br />
breakthrough technology to discover highly potent antibodies on behalf of its partners in the pharmaceutical<br />
industry.<br />
MANAGEMENT<br />
David Urech, PhD, CSO & Co-CEO<br />
Oliver Middendorp, PhD, CBO & Co-CEO<br />
Tea Gunde, PhD, Head of Pharmacology<br />
Sebastian Meyer, PhD, Head of Biochemistry<br />
Roland Helfenstein, Head of Finance and Administration<br />
t back :: next u<br />
WELCOME PHARMA LICENSING GROUPS<br />
SPEAKERS<br />
PRESENTING COMPANIES SUPPORTING ORGANISATIONS<br />
ORGANISERS
Change language